港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

中慧生物-B

53.250

+0.6501.24%

成交量：45.72万

成交额：2,413.04万

市值：209.51亿

市盈率：-67.99

高：53.950

开：53.950

低：51.400

收：52.600

52周最高：59.600

52周最低：33.000

股本：3.93亿

香港流通股本：2.96亿

量比：0.89

换手率：0.15%

股息：- -

股息率：- -

每股收益(LYR):-0.783

净资产收益率：--

总资产收益率：--

市净率：309.16

市盈率(LYR):-67.99

市销率: 74.01

数据加载中...

总览公司新闻公告

【新股IPO】江苏中慧元通生物科技股份有限公司通过港交所上市聆讯

IPO资讯 | 中慧元通-B通过聆讯，将于本周内开启招股；澜起科技增聘香港上市整体协调人，全球最大的内存互连芯片供应商

中慧生物创新疫苗平台筑壁垒单一产品依赖到多品类突围的挑战

中国上市公司网

一周港股IPO观察：9家递表企业涵盖智能传感、碳化硅等赛道

中国上市公司网

中慧生物：手握高端疫苗单品业绩暴增，仍难破行业内卷困局？

中慧生物：手握高端疫苗单品业绩暴增，仍难破行业内卷困局？

智通财经APP

中慧生物上市聆讯获通过拟于港交所主板上市

中国上市公司网

一周IPO观察：维立志博超40倍国配首日近翻倍，歌尔微、天域半导体等递表；设计软件独角兽Figma美股上市在即

中慧元通通过上市聆讯：年营收2.6亿亏损2.59亿估值42亿

建筑大佬“跨界”创新疫苗，近9亿借款现还债危机

阿尔法工场研究院

中惠生物更新招股书：仅一款疫苗商业化，市场已成“红海”

经济观察网

港股IPO周报：维立志博-B上市首日爆升92%，成18A新股又一“肉签”，新增迈瑞医疗等6家A to H公司

中惠生物更新招股书：仅一款疫苗商业化，市场已成“红海”

经济观察网

港股IPO周报：歌尔微电子等多家公司递表维立志博挂牌首日大涨约九成

这家疫苗企业再冲IPO！亏损扩大！

IPO日报国际金...

IPO一周要闻丨1家上会今年首家上会被暂缓审议企业

这家疫苗企业再冲IPO！亏损扩大

国际金融报

中慧生物IPO：流感疫苗每针319元，拒绝价格内卷，能逃离产业寒冬吗？

中慧生物更新港交所招股书：有一款商业化产品，2024年营收增长四倍

【新股IPO】江苏中慧元通携中国唯一获批的四价流感病毒亚单位疫苗再闯港交所

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02627/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02627","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","market":"HK","secType":"STK","nameCN":"中慧生物-B","latestPrice":53.25,"timestamp":1756194208915,"preClose":52.6,"halted":0,"volume":457200,"delay":0,"floatShares":296361845,"shares":393442600,"eps":-0.7832559755678713,"marketStatus":"交易中","change":0.65,"latestTime":"08-26 15:43:59","open":53.95,"high":53.95,"low":51.4,"amount":24130400,"amplitude":0.048479,"askPrice":53.4,"askSize":10400,"bidPrice":53.25,"bidSize":4400,"shortable":0,"etf":0,"ttmEps":-0.8558732663960658,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1756195800000},"marketStatusCode":2,"adr":0,"listingDate":1754841600000,"exchange":"SEHK","adjPreClose":52.6,"openAndCloseTimeList":[[1756171800000,1756180800000],[1756184400000,1756195200000]],"volumeRatio":0.890673,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","floatShares":296361845,"roa":"--","roe":"--","lyrEps":-0.783256,"volumeRatio":0.890673,"shares":393442600,"dividePrice":0,"high":53.95,"amplitude":0.048479,"preClose":52.6,"low":51.4,"week52Low":33,"pbRate":"309.16","psRate":"74.01","week52High":59.6,"institutionHeld":0,"latestPrice":53.25,"committee":-0.405405,"eps":-0.7832559755678713,"divideRate":0,"volume":457200,"delay":0,"ttmEps":-0.8558732663960658,"open":53.95,"prevYearClose":12.9,"prevWeekClose":51.5,"prevMonthClose":12.9,"prevQuarterClose":12.9,"fiveDayClose":51.55,"twentyDayClose":12.9,"sixtyDayClose":12.9,"earningDate":1756310400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02627\",params:#limit:5,,,undefined,":[{"date":"2025-08-28","symbol":"02627","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756344600000,"name":null,"time":"","dateTimestamp":1756310400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02627\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02627\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02627\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02627","date":"2025-08-25","current":-67.012733,"percent":0.090909,"low":-68.430715,"twenty":-66.312405,"median":-63.829854,"eighty":-55.968526,"high":-18.07815,"avg":-57.901075,"sd":13.845669,"marketCap":20695080760},"quantilePoints":[{"date":"2025-08-08","current":-18.07815,"twenty":-18.07815,"median":-18.07815,"eighty":-18.07815,"marketCap":5586884920},{"date":"2025-08-15","current":-60.155426,"twenty":-60.155426,"median":-56.438909,"eighty":-42.414982,"marketCap":18562621868},{"date":"2025-08-22","current":-65.870069,"twenty":-65.897052,"median":-63.746879,"eighty":-55.654938,"marketCap":20262293900},{"date":"2025-08-25","current":-67.012733,"twenty":-66.312405,"median":-63.829854,"eighty":-55.968526,"marketCap":20695080760}],"updateTime":1756186954113},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02627\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2554772776","title":"【新股IPO】江苏中慧元通生物科技股份有限公司通过港交所上市聆讯","url":"https://stock-news.laohu8.com/highlight/detail?id=2554772776","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554772776?lang=zh_cn&edition=fundamental","pubTime":"2025-07-28 21:31","pubTimestamp":1753709472,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所7月27日披露，江苏中慧元通生物科技股份有限公司通过港交所上市聆讯，中信证券、招银国际为联席保荐人。公司是一家总部位于中国的疫苗公司，致力于创新疫苗及采用新技术方法的传统疫苗的研发、制造及商业化。对应同期，研发开支为2.83亿元、2.06亿元、4651.4万元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/Mjg2ODEwOTEwOTU2Mw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Mjg2ODEwOTEwOTU2Mw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1963023","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEXmain","02627","159837"],"gpt_icon":0},{"id":"2554721217","title":"IPO资讯 | 中慧元通-B通过聆讯，将于本周内开启招股；澜起科技增聘香港上市整体协调人，全球最大的内存互连芯片供应商","url":"https://stock-news.laohu8.com/highlight/detail?id=2554721217","media":"华通玖安","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554721217?lang=zh_cn&edition=fundamental","pubTime":"2025-07-28 15:30","pubTimestamp":1753687824,"startTime":"0","endTime":"0","summary":"中慧元通已于6月26日获中国证监会境外发行上市及境内未上市股份“全流通”备案，最早将于本周内开启招股。中慧元通财务数据2澜起科技增聘香港上市整体协调人全球最大的内存互连芯片供应商港交所7月25日披露，澜起科技股份有限公司进一步委任高盛、中信里昂为整体协调人。根据弗若斯特沙利文的资料，按2024年的收入计算，澜起科技是全球最大的内存互连芯片供应商，市场份额为36.8%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728161128a46746dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728161128a46746dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159813","02627","688008","LU2039709279.SGD","BK0214"],"gpt_icon":0},{"id":"2554104772","title":"中慧生物 创新疫苗平台筑壁垒 单一产品依赖到多品类突围的挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2554104772","media":"中国上市公司网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554104772?lang=zh_cn&edition=fundamental","pubTime":"2025-07-28 15:25","pubTimestamp":1753687500,"startTime":"0","endTime":"0","summary":"2025年7月24日，江苏中慧元通生物科技股份有限公司 Ab&B Bio-Tech CO.,LTD.JS(以下简称”中慧生物或公司”)向港交所递交招股书，拟香港主板挂牌上市。中慧生物，于2025年6月25日获中国 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250728/c669942584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159646","02627"],"gpt_icon":0},{"id":"2555704826","title":"一周港股IPO观察：9家递表企业涵盖智能传感、碳化硅等赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2555704826","media":"中国上市公司网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555704826?lang=zh_cn&edition=fundamental","pubTime":"2025-07-28 15:21","pubTimestamp":1753687260,"startTime":"0","endTime":"0","summary":"据统计，7月21日至7月27日期间，港股市场共有9家公司提交招股书，暂无公司通过聆讯。此外，有0家公司招股，1家公司上市。一、递表(9家)1)、7月21日，歌尔微电子第二次向港交所递交招股书， ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250728/c669942514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["02627"],"gpt_icon":0},{"id":"2554728124","title":"中慧生物：手握高端疫苗单品业绩暴增，仍难破行业内卷困局？","url":"https://stock-news.laohu8.com/highlight/detail?id=2554728124","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554728124?lang=zh_cn&edition=fundamental","pubTime":"2025-07-28 13:21","pubTimestamp":1753680086,"startTime":"0","endTime":"0","summary":"手握高端疫苗单品，商业化兑现却存疑中慧生物成立于2015年10月，公司主要致力于创新疫苗及采用新技术方法的传统疫苗的研发、制造及商业化。招股书显示，2024年中慧生物收入同比大幅增长397.65%，2025Q1季度营收同比增长34.97%。中慧生物能在“内卷”行业立足的一大关键在于其具备差异化技术优势的高端疫苗产品路线。临床结果显示，中慧生物四价流感病毒亚单位疫苗的H1N1、H3N2、BV及BY病毒株的血清保护率分别为96.56%、97.98%、89.41%及95.88%，均高于欧盟标准70.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","02627"],"gpt_icon":0},{"id":"2554724088","title":"中慧生物：手握高端疫苗单品业绩暴增，仍难破行业内卷困局？","url":"https://stock-news.laohu8.com/highlight/detail?id=2554724088","media":"智通财经APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554724088?lang=zh_cn&edition=fundamental","pubTime":"2025-07-28 13:21","pubTimestamp":1753680086,"startTime":"0","endTime":"0","summary":"手握高端疫苗单品，商业化兑现却存疑中慧生物成立于2015年10月，公司主要致力于创新疫苗及采用新技术方法的传统疫苗的研发、制造及商业化。招股书显示，2024年中慧生物收入同比大幅增长397.65%，2025Q1季度营收同比增长34.97%。中慧生物能在“内卷”行业立足的一大关键在于其具备差异化技术优势的高端疫苗产品路线。临床结果显示，中慧生物四价流感病毒亚单位疫苗的H1N1、H3N2、BV及BY病毒株的血清保护率分别为96.56%、97.98%、8 9.41%及95.88%，均高于欧盟标准70.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8lM6qSkviC1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["02627","159646"],"gpt_icon":0},{"id":"2554772835","title":"中慧生物上市聆讯获通过 拟于港交所主板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2554772835","media":"中国上市公司网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554772835?lang=zh_cn&edition=fundamental","pubTime":"2025-07-28 12:36","pubTimestamp":1753677360,"startTime":"0","endTime":"0","summary":"中国上市公司网讯 7月27日，江苏中慧元通生物科技股份有限公司(以下简称“中慧生物”)上市聆讯获通过，公司将登陆港交所主板上市，联席保荐人为中信证券和招银国际。公开数据显示，中慧生物 ...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250728/c669940090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["02627"],"gpt_icon":0},{"id":"2554747121","title":"一周IPO观察：维立志博超40倍国配首日近翻倍，歌尔微、天域半导体等递表；设计软件独角兽Figma美股上市在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2554747121","media":"FX168","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554747121?lang=zh_cn&edition=fundamental","pubTime":"2025-07-28 11:18","pubTimestamp":1753672717,"startTime":"0","endTime":"0","summary":"截止2025年的第30周，港交所无新股上市，1家上市，1家招股，1家聆讯，9家递表。维立志博-B招股结束并于7月25日上市，募资12.90亿港元，市场申购火热，国配超40倍。7月25日，福建乐摩物联科技向港交所递交招股书，拟香港主板挂牌上市。7月22日，维立志博-B开启招股，并预计于2025年7月25日在港交所挂牌上市，摩根士丹利、中信证券为其联席保荐人","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fx168news.com/article/921974","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","FIG","02627"],"gpt_icon":1},{"id":"2554380742","title":"中慧元通通过上市聆讯：年营收2.6亿亏损2.59亿 估值42亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2554380742","media":"雷递网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554380742?lang=zh_cn&edition=fundamental","pubTime":"2025-07-28 08:56","pubTimestamp":1753664164,"startTime":"0","endTime":"0","summary":"江苏中慧元通生物科技股份有限公司（简称：“中慧元通”）日前通过上市聆讯，准备在港交所上市。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250728/6388928976115386892592037.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250728/6388928976115386892592037.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n30660/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["02627"],"gpt_icon":0},{"id":"2555081675","title":"建筑大佬“跨界”创新疫苗，近9亿借款现还债危机","url":"https://stock-news.laohu8.com/highlight/detail?id=2555081675","media":"阿尔法工场研究院","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555081675?lang=zh_cn&edition=fundamental","pubTime":"2025-07-28 08:00","pubTimestamp":1753660800,"startTime":"0","endTime":"0","summary":"截至2025年3月31日，中慧元通债务总额约9.44亿元，而银行借款约8.96亿元，其中一年内到期的银行借款约4.06亿元。与此相比，中慧元通同期持有的现金及现金等价物仅1.15亿元，偿债压力较大。中慧元通预计二号生产园区的设计年产能为1000万剂流感疫苗，其建设资金主要来自信贷融资额度和经营所得现金。值得注意的是，中慧元通表示，在公司重组疫苗商业化之前，预计未来三年内三号生产园区的利用率较低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MjM5MzAzNzE0MQ==&mid=2651592553&idx=3&sn=e7137435ab235fd9d4ae44bee0846f8d&chksm=bc41cf027ebfacd882b96705d088232cce6606db24ffead4df5547527f3982616b3a54b7906b&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["02627"],"gpt_icon":0},{"id":"2554106748","title":"中惠生物更新招股书：仅一款疫苗商业化，市场已成“红海”","url":"https://stock-news.laohu8.com/highlight/detail?id=2554106748","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554106748?lang=zh_cn&edition=fundamental","pubTime":"2025-07-27 17:25","pubTimestamp":1753608300,"startTime":"0","endTime":"0","summary":"7月24日，江苏中慧元通生物科技股份有限公司（下称“中慧生物”）在港交所再次递表，招股书显示，公司目前仅有一款四价流感病毒亚单位疫苗实现商业化，且尚未实现年度盈利。中慧生物2025年1 ...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20250727/c669928386.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250727/c669928386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["02627","159646"],"gpt_icon":0},{"id":"2554482477","title":"港股IPO周报：维立志博-B上市首日爆升92%，成18A新股又一“肉签”，新增迈瑞医疗等6家A to H公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2554482477","media":"活报告","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554482477?lang=zh_cn&edition=fundamental","pubTime":"2025-07-27 17:17","pubTimestamp":1753607820,"startTime":"0","endTime":"0","summary":"市场消息称，传音控股、迈瑞医疗两家A股公司拟赴港上市，两家均拟募资10亿美元。截至目前，除已上市的10家外，已有76家A股公司已递表港交所或官宣赴港上市。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/cj/2025-07-27/doc-infhxefu2680348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1734074674.USD","IE00B29SXG58.USD","LU0359202008.SGD","LU1997245094.SGD","LU1655091616.SGD","IE00B031J352.USD","HSCEI","IE00B031HY20.USD","LU1146622755.USD","LU2488822045.USD","LU1979443071.USD","LU1580142542.USD","IE0031814852.USD","LU1064131003.USD","LU1720050803.USD","BK0251","IE0008368742.USD","LU0650527681.SGD","02627","07226","LU2424517915.HKD","300760","LU1023057109.AUD","LU0594300419.USD","LU0405327148.USD","LU0605514214.HKD","LU0823426308.USD","LU2348773727.SGD","IE0005HP3H50.USD","LU0572944931.SGD","LU2148510915.USD","LU0594300179.USD","LU2348774022.SGD","SGXZ49509284.SGD","SGXZ81163826.USD","LU1794554557.SGD","LU2153591404.USD","LU0327786744.USD","LU2213484517.USD","LU1064130708.USD","LU0405327494.USD","LU0084288322.USD","LU2153592121.USD","LU0823426480.USD","LU0359201612.USD","YANG","LU1997245177.USD","HSTECH","LU1820825898.SGD","LU1781817850.SGD"],"gpt_icon":1},{"id":"2554274867","title":"中惠生物更新招股书：仅一款疫苗商业化，市场已成“红海”","url":"https://stock-news.laohu8.com/highlight/detail?id=2554274867","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554274867?lang=zh_cn&edition=fundamental","pubTime":"2025-07-27 16:57","pubTimestamp":1753606620,"startTime":"0","endTime":"0","summary":"7月24日，江苏中慧元通生物科技股份有限公司在港交所再次递表，招股书显示，公司目前仅有一款四价流感病毒亚单位疫苗实现商业化，且尚未实现年度盈利。中慧生物招股书相关注释统计，中国流感疫苗的平均投标价格由2022年的每剂人民币126元降至2023年的每剂人民币125元，2024年进一步降至每剂人民币93元。对于中慧生物而言，其核心产品已身处“红海”市场，未来或将面临更为激烈的竞争。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-07-27/doc-infhxefs5901357.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-07-27/doc-infhxefs5901357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02627","159646"],"gpt_icon":0},{"id":"2554671747","title":"港股IPO周报：歌尔微电子等多家公司递表 维立志博挂牌首日大涨约九成","url":"https://stock-news.laohu8.com/highlight/detail?id=2554671747","media":"财联社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554671747?lang=zh_cn&edition=fundamental","pubTime":"2025-07-27 12:29","pubTimestamp":1753590545,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K5FMKS6P05198CJN.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K5FMKS6P05198CJN.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02627"],"gpt_icon":0},{"id":"2554129707","title":"这家疫苗企业再冲IPO！亏损扩大！","url":"https://stock-news.laohu8.com/highlight/detail?id=2554129707","media":"IPO日报国际金...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554129707?lang=zh_cn&edition=fundamental","pubTime":"2025-07-27 08:30","pubTimestamp":1753576200,"startTime":"0","endTime":"0","summary":"截至最后实际可行日期，除2种核心产品外，中慧元通的产品管线还包括其他11种在研疫苗，涵盖多种有疫苗接种需求的疾病领域。相比之下，2024年前3个月，中慧元通营收和净利润为30.6万元、-6333万元，这意味着，中慧元通2025年前3个月收入同比增长，净利润亏损却有所扩大。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/cj/2025-07-27/doc-infhwiaf7049837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159646","02627"],"gpt_icon":0},{"id":"2554712300","title":"IPO一周要闻丨1家上会 今年首家上会被暂缓审议企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2554712300","media":"投资者网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554712300?lang=zh_cn&edition=fundamental","pubTime":"2025-07-27 08:01","pubTimestamp":1753574492,"startTime":"0","endTime":"0","summary":"截至目前最高涨幅124%。四、市场动态：立讯精密拟赴港上市7月23日，立讯精密发布公告称，公司董事会审议通过了发行H股股票并在香港联交所主板上市的议案。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/27080152006998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","LU1328615791.USD","LU1242518857.USD","BK0026","BK0183","LU1064130708.USD","BK0072","BK0109","BK0196","BK0121","LU2148510915.USD","02627","002241","BK0175","LU1242518931.SGD","BK0108","BK0070","BK0187","BK0197","BK0214","LU1064131003.USD","LU0979878070.USD","BK0028"],"gpt_icon":0},{"id":"2554111447","title":"这家疫苗企业再冲IPO！亏损扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2554111447","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554111447?lang=zh_cn&edition=fundamental","pubTime":"2025-07-26 22:47","pubTimestamp":1753541220,"startTime":"0","endTime":"0","summary":"7月24日，江苏中慧元通生物科技股份有限公司（下称：“中慧元通”）二次递表，准备在港交所上市。这是继2025年1月23日递表未果后的再次努力。此前，2023年6月，中慧元通曾寻求在上交所科创 ...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20250726/c669926039.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250726/c669926039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["02627","159646"],"gpt_icon":0},{"id":"2554944790","title":"中慧生物IPO：流感疫苗每针319元，拒绝价格内卷，能逃离产业寒冬吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2554944790","media":"TMTPost","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554944790?lang=zh_cn&edition=fundamental","pubTime":"2025-07-26 08:55","pubTimestamp":1753491310,"startTime":"0","endTime":"0","summary":null,"market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tmtpost.com/7638600.html?rss=laohu8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"gpt_icon":0},{"id":"2554762446","title":"中慧生物更新港交所招股书：有一款商业化产品，2024年营收增长四倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2554762446","media":"瑞财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554762446?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 19:31","pubTimestamp":1753443062,"startTime":"0","endTime":"0","summary":"公司在中国有一款商业化产品四价流感病毒亚单位疫苗，其于2023年5月获得国家药监局的NDA批准，可用于三岁及以上人群，于2023年9月开始销售。中慧生物的全部收入均来自销售四价流感病毒亚单位疫苗，销售业绩存在季节性波动，2024年因疫苗销售而收入爆发式增长，亏损也有所收窄。2024年，中慧生物的营业收入同比增长了400%，净亏损有所收窄。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072519312694ba7654&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072519312694ba7654&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02627","00388","80388"],"gpt_icon":1},{"id":"2554750868","title":"【新股IPO】江苏中慧元通携中国唯一获批的四价流感病毒亚单位疫苗再闯港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2554750868","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554750868?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 16:32","pubTimestamp":1753432348,"startTime":"0","endTime":"0","summary":"商品名为慧尔康欣的四价流感病毒亚单位疫苗于2023年5月获国家药监局的NDA批准，可用于三岁及以上人群。其成为截至最后实际可行日期在中国获批的首款且唯一一款四价流感病毒亚单位疫苗。自此，中国四价流感疫苗市场显著增长。此外，于2024年，三价和四价灭活流感疫苗价格同时下降。","market":"hk","thumbnail":"https://static.szfiu.com/news/20220324/YjY3NDkzOTMxMjg3NTcxMDI1Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/YjY3NDkzOTMxMjg3NTcxMDI1Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1962921","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEXmain","159646","02627"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":89,"code":"91000000","status":"200"}]}}